Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] EXAMINE: targeting risk and treatment in diabetes

Type 2 diabetes mellitus is associated with both microvascular and macrovascular complications. For this reason, the US Food and Drug Administration includes specific requirements for cardiovascular safety assessment before the approval of new anti-diabetic drugs. In 2006, a population-based case-control study1 showed a significantly increased risk of myocardial infarction in patients using glibenclamide. That same year, the ADOPT study2 revealed an increase in the incidence of heart failure with rosiglitazone compared with glibenclamide (hazard ratio [HR] 2·20, 95% CI 1·01–4·79; p=0·05).

email